Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ARS PharmaceuticalsSPRY +1.51%28 Net Margin % is -267.26% as of Mar. 2026. GuruFocus rates SPRY with a GF Score™ of 28/100. The stock has 5 warning signs investors should review. Among 945 Biotechnology companies, ARS Pharmaceuticals ranks worse than 60.95% on this metric.
ARS Pharmaceuticals (NAS:SPRY) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
ARS Pharmaceuticals Net Margin % Related Terms
ARS Pharmaceuticals Net Margin % Historical Data
* Premium members only.
The historical data trend for ARS Pharmaceuticals's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ARS Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ARS Pharmaceuticals Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ARS Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where ARS Pharmaceuticals's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARS Pharmaceuticals (SPRY) has a Net Margin % of -267.26% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on ARS Pharmaceuticals and its competitors. According to the industry distribution chart, ARS Pharmaceuticals ranks #576 out of 945 companies in the Biotechnology industry, placing it in the top 61%.
Is ARS Pharmaceuticals' Net Margin % too high?
ARS Pharmaceuticals' current Net Margin % is -267.26%. Based on the distribution chart, ARS Pharmaceuticals ranks #576 out of 945 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ARS Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does ARS Pharmaceuticals' Net Margin % compare to ALLO and CBIO?
According to the Biotechnology industry distribution chart, ARS Pharmaceuticals ranks #576 out of 945 companies for Net Margin %. This places ARS Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on ARS Pharmaceuticals and its competitors. ARS Pharmaceuticals's current Net Margin % is -267.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ARS Pharmaceuticals stock overvalued right now?
ARS Pharmaceuticals (SPRY) has a current Net Margin % of -267.26%. The current Net Margin % is -267.26%. ARS Pharmaceuticals' overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For ARS Pharmaceuticals (SPRY), the current Net Margin % is -267.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
28GF Score
Get the complete analysis for SPRY
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRY has been successfully added to your 
